Aurinia Pharmaceuticals Inc. (AUPH) Shares Down 3.8%
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)’s share price dropped 3.8% during trading on Friday . The company traded as low as $3.61 and last traded at $4.10, with a volume of 237,018 shares. The stock had previously closed at $4.26.
AUPH has been the topic of several analyst reports. Zacks Investment Research lowered shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, May 5th. Canaccord Genuity reaffirmed a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Thursday, May 12th. HC Wainwright initiated coverage on shares of Aurinia Pharmaceuticals in a report on Thursday, June 30th. They issued a “buy” rating and a $7.00 price target on the stock. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $7.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 6th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Aurinia Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $7.15.
The firm’s 50 day moving average price is $3.17 and its 200 day moving average price is $2.76. The company’s market cap is $132.05 million.
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.